JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HARRIS, P. N.
Right arrow Articles by CHEN, K. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by HARRIS, P. N.
Right arrow Articles by CHEN, K. K.
Journal of Pharmacology And Experimental Therapeutics, Vol. 75, Issue 1, 78-82, 1942
Copyright © 1942 by American Society for Pharmacology and Experimental Therapeutics

THE ACTION OF MONOCROTALINE AND RETRONECINE

PAUL N. HARRIS 1, ROBERT C. ANDERSON 1, and K. K. CHEN 1

1 From the Lilly Research Laboratories, Eli Lilly and Company, Indianapolis

1. The acute toxicity of monocrotaline and retronecine has been determined in mice.

2. Monocrotaline produces liver necrosis associated with sinusoidal congestion and hemorrhage into necrotic cell cords. Repeated administration of monocrotaline appears to cause hypertrophy of liver cells.

3. Intravenous injection of large doses of retronecine is followed by either rapid death or complete recovery. No hepatic injury has resulted.

4. Monocrotaline inhibits isolated rabbits' intestines, and has a slight depressor action in cats. Retronecine reduces cats' blood pressure in relatively large doses, and stimulates the isolated guinea pig's uterus. In dilute concentration, retronecine inhibits isolated rabbits' intestines, but in stronger solutions, it augments them.

Submitted on February 2, 1942




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
A. L. Zaiman, M. Podowski, S. Medicherla, K. Gordy, F. Xu, L. Zhen, L. A. Shimoda, E. Neptune, L. Higgins, A. Murphy, et al.
Role of the TGF-{beta}/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 896 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Mukhopadhyay, F. Xu, and P. B. Sehgal
Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia, and senescence: live-cell caveolar and cytoplasmic NO imaging
Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1373 - H1389.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. Mukhopadhyay and P. B. Sehgal
Discordant regulatory changes in monocrotaline-induced megalocytosis of lung arterial endothelial and alveolar epithelial cells
Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1216 - L1226.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. Shah, K. Patel, and P. B. Sehgal
Monocrotaline pyrrole-induced endothelial cell megalocytosis involves a Golgi blockade mechanism
Am J Physiol Cell Physiol, April 1, 2005; 288(4): C850 - C862.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1942 by the American Society for Pharmacology and Experimental Therapeutics.